Roche reports enicepatide results. Roche Holding stock gains 1.27 percent

Published on 10/05/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enicepatide cut HbA1c 2.65 percent at 48 weeks. Roche Holding stock costs EUR 377.30 on October 5, 2026 after EUR 372.58, plus 1.27 percent.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 377.30 at Lang & Schwarz on October 5, 2026 at 1:35 p.m. CEST, up 1.27 percent versus the prior close of EUR 372.58. The company reported positive Phase II enicepatide results on September 22, 2026, with the highest dose producing a 2.65 percent reduction in HbA1c at 48 weeks, according to Roche.

Enicepatide reaches key endpoints

The 24 mg enicepatide group also recorded mean weight loss of 15.50 percent at 48 weeks, while 90.00 percent of participants reached an HbA1c level at or below 6.50 percent, Roche said in the September 22, 2026 release. The study enrolled 447 adults with type 2 diabetes and overweight or obesity, giving the result a broader clinical base than a small early-stage trial.

The safety profile was consistent with the incretin class, and treatment discontinuation caused by adverse events was 2.00 percent in the enicepatide arms versus 0.00 percent for placebo, according to Roche. Roche is advancing two Phase III studies in chronic weight management and plans further Phase III work on glucose control in the first half of 2027.

Sales update comes October 22

The next scheduled company milestone is Roche's third-quarter sales presentation on October 22, 2026, at 2:00 p.m. CEST, according to the Roche investor page. That date gives the market a near-term checkpoint for sales trends before the clinical pipeline becomes the main valuation discussion.

Roche's investor materials show core earnings per share growth of 11.00 percent at constant exchange rates in fiscal year 2025, to CHF 19.46, and 39 million patients treated with Roche medicines during that year, according to Roche. The combination of established earnings and a late-stage cardiometabolic pipeline leaves the October sales update as the next measurable test for the stock.

Roche stock rises in trading

Roche Holding stock was trading at EUR 377.30 at Lang & Schwarz on October 5, 2026 at 1:35 p.m. CEST, compared with a prior close of EUR 372.58. The participation certificate is listed on SIX Swiss Exchange under ticker ROP, and the security identified by ISIN CH1499059983 is Roche's participation certificate, according to Roche. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.